ABERA BIOSCIENCE AB (8WK) - Total Liabilities
Based on the latest financial reports, ABERA BIOSCIENCE AB (8WK) has total liabilities worth €7.57 Million EUR (≈ $8.84 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 8WK net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
ABERA BIOSCIENCE AB - Total Liabilities Trend (2022–2025)
This chart illustrates how ABERA BIOSCIENCE AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 8WK current and non-current assets.
ABERA BIOSCIENCE AB Competitors by Total Liabilities
The table below lists competitors of ABERA BIOSCIENCE AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Neuroscientific Biopharmaceuticals Ltd
AU:NSB
|
Australia | AU$207.87K |
|
Australian Agricultural Projects Ltd
AU:AAP
|
Australia | AU$7.55 Million |
|
Aelis Farma SA
PA:AELIS
|
France | €9.46 Million |
|
Lifestyle Global Enterprise
TWO:8066
|
Taiwan | NT$901.60 Million |
|
Tong Hua Holding Public Company Limited
BK:TH
|
Thailand | ฿40.80 Million |
|
Lode Resources Ltd
AU:LDR
|
Australia | AU$1.66 Million |
|
Yesil Yatirim Holding AS
IS:YESIL
|
Turkey | TL6.37 Million |
|
Hanan Mor
TA:HNMR
|
Israel | ILA2.84 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down ABERA BIOSCIENCE AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ABERA BIOSCIENCE AB balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABERA BIOSCIENCE AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABERA BIOSCIENCE AB (2022–2025)
The table below shows the annual total liabilities of ABERA BIOSCIENCE AB from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €9.28 Million ≈ $10.85 Million |
+87.59% |
| 2024-12-31 | €4.95 Million ≈ $5.78 Million |
+33.96% |
| 2023-12-31 | €3.69 Million ≈ $4.32 Million |
+32.13% |
| 2022-12-31 | €2.80 Million ≈ $3.27 Million |
-- |
About ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead va… Read more